November 25, 2016 - By Linda Rogers · 0 Comments
The stock of Biogen Incorporated (NASDAQ:BIIB) registered a decrease of 7.22% in short interest. BIIB’s total short interest was 2.36M shares in November as published by FINRA. Its down 7.22% from 2.55M shares, reported previously. With 1.52 million shares average volume, it will take short sellers 2 days to cover their BIIB’s short positions. The stock decreased 0.24% or $0.73 during the last trading session, hitting $305.2. About 740,920 shares traded hands. Biogen Inc (NASDAQ:BIIB) has risen 8.22% since April 22, 2016 and is uptrending. It has outperformed by 2.81% the S&P500.
Biogen Inc., formerly Biogen Idec Inc., is a biopharmaceutical company. The company has a market cap of $63.86 billion. The Firm operates in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment. It has a 17.26 P/E ratio. The Firm markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis , ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis.
Insitutional Activity: The institutional sentiment decreased to 1 in Q2 2016. Its down 0.03, from 1.03 in 2016Q1. The ratio dropped, as 77 funds sold all Biogen Inc shares owned while 300 reduced positions. 83 funds bought stakes while 307 increased positions. They now own 183.84 million shares or 8.46% less from 200.84 million shares in 2016Q1.
Gateway Invest Advisers Limited holds 0.36% or 173,476 shares in its portfolio. Mitchell Cap Management Communication holds 21,191 shares or 2.05% of its portfolio. Keybank Association Oh, a Ohio-based fund reported 10,735 shares. Baxter Bros holds 0.14% or 1,618 shares in its portfolio. Callan Llc has 3,644 shares for 0.36% of their US portfolio. Bartlett & Limited Liability Company reported 51 shares or 0% of all its holdings. Terril Brothers Incorporated last reported 65,573 shares in the company. Dowling Yahnke Llc has invested 0.17% of its portfolio in Biogen Inc (NASDAQ:BIIB). Asset Advsrs Corp, a Georgia-based fund reported 1,000 shares. Sphera Funds Mngmt Ltd holds 50,500 shares or 3.17% of its portfolio. Osborne Partners Capital Management Lc owns 2,695 shares or 0.1% of their US portfolio. Alphamark Advisors Lc accumulated 4 shares or 0% of the stock. Moreover, Cantab Cap Prtnrs Llp has 0% invested in Biogen Inc (NASDAQ:BIIB) for 706 shares. Philadelphia accumulated 101,620 shares or 2.13% of the stock. Highvista Strategies holds 46,200 shares or 2.14% of its portfolio.
Insider Transactions: Since May 31, 2016, the stock had 0 insider buys, and 6 sales for $10.26 million net activity. DORSA CAROLINE also sold $8.66 million worth of Biogen Inc (NASDAQ:BIIB) on Thursday, September 22. Another trade for 842 shares valued at $244,180 was sold by SCANGOS GEORGE A. Karaboutis Adriana sold $81,728 worth of stock or 262 shares.
Out of 18 analysts covering Biogen Idec Inc. (NASDAQ:BIIB), 13 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 72% are positive. Biogen Idec Inc. has been the topic of 34 analyst reports since July 23, 2015 according to StockzIntelligence Inc. The stock of Biogen Inc (NASDAQ:BIIB) has “Buy” rating given on Thursday, January 7 by Standpoint Research. The rating was downgraded by Jefferies on Tuesday, September 6 to “Hold”. Jefferies maintained it with “Hold” rating and $316 target price in Wednesday, October 5 report. The firm has “Neutral” rating given on Wednesday, January 20 by Credit Suisse. The stock of Biogen Inc (NASDAQ:BIIB) has “Overweight” rating given on Monday, November 7 by PiperJaffray. The firm has “Outperform” rating given on Monday, July 27 by RBC Capital Markets. Raymond James maintained it with “Strong Buy” rating and $375 target price in Tuesday, August 2 report. The stock of Biogen Inc (NASDAQ:BIIB) earned “Buy” rating by Citigroup on Thursday, February 25. The stock of Biogen Inc (NASDAQ:BIIB) has “Buy” rating given on Wednesday, September 9 by Jefferies. Argus Research maintained Biogen Inc (NASDAQ:BIIB) rating on Monday, July 27. Argus Research has “Buy” rating and $360 price target.
Biogen Inc., formerly Biogen Idec Inc., incorporated on April 1, 1997, is a biopharmaceutical company. The Firm operates in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment. The Firm markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis. The Firm also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other potential anti-CD20 therapies.
More notable recent Biogen Inc (NASDAQ:BIIB) news were published by: Fool.com which released: “Better Buy: Biogen Inc. vs. Celgene Corporation” on November 15, 2016, also Businesswire.com with their article: “SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Biogen Inc …” published on November 25, 2016, Etfdailynews.com published: “Biogen Shares Hammered On Ely Lilly’s Drug Failure” on November 23, 2016. More interesting news about Biogen Inc (NASDAQ:BIIB) were released by: Fool.com and their article: “Why Biogen Inc. Stock Lost 10.5% of Its Value In October” published on November 09, 2016 as well as Fool.com‘s news article titled: “Biogen Inc. Working With What It’s Got as It Looks to Diversify” with publication date: October 27, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Linda Rogers